Oncolytics Biotech Inc. (ONCY) Q1 2024 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Oncolytics Biotech Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.029 -- 00:00:05.093 Good afternoon and welcome to Oncolytics Biotech's first quarter 2024 conference 00:00:05.093 -- 00:00:09.516 call. All participants are now in listen-only mode. 00:00:09.516 -- 00:00:13.359 There will be a question and answer session at the end of this call. 00:00:13.359 -- 00:00:18.023 Please be advised that this call is being recorded at the company's request. 00:00:18.023 -- 00:00:22.646 I would now like to turn the call over to John Patton, Director of Investor Relations 00:00:22.646 -- 00:00:24.728 and Communication. Please go ahead. 00:00:24.728 -- 00:00:28.211 Thank you, Operator, and good afternoon, everyone. 00:00:28.211 -- 00:00:32.394 Earlier today, OnClinic's issued a press release providing recent operational highlights 00:00:32.394 -- 00:00:34.155 and financial results for the first quarter of 2024. 00:00:34.155 -- 00:00:39.198 A replay of today's call will be available on the event section of the OnClinic's 00:00:39.198 -- 00:00:42.200 website approximately two hours after its completion. 00:00:42.200 -- 00:00:45.662 After remarks from company management, we will open the call for Q&A. 00:00:45.662 -- 00:00:48.924 As a reminder, various remarks made during this call contain certain forward-looking 00:00:48.924 -- 00:00:52.787 statements relating to the company's business prospects and the development and commercialization 00:00:52.787 -- 00:00:56.495 of Pellegrino Rep. Including statements regarding the company's mission, the company's 00:00:56.495 -- 00:01:01.077 belief as an essential and mechanism of action of Pellery Rep as a cancer therapeutic, 00:01:01.077 -- 00:01:05.400 our belief that we are positioned to begin registrational track studies in breast and 00:01:05.400 -- 00:01:09.862 pancreatic cancer, and ou...